NCT05411965 - A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

July 3, 2022

Study Completion Date

July 3, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BR3003(T)

"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."

DRUG

BR3003B(R1)

"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."

DRUG

BR3003C(R2)

"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"

Trial Locations (1)

Clinical Research Center, H PLUS Yangji Hospital, Seoul